Belgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of a €10 million investment from Japanese business conglomerate ITOCHU Corp
Sanofi and Merck & Co picked up late 2018 approval from the FDA during the holiday period, getting a green light for their six-in-one paediatric shot Vaxelis.
US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and
Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering t
